Johnson & Johnson has been at the center of controversy as of late. The multinational pharmaceutical company faces backlash for its alleged role an opioid crisis in Oklahoma as prosecutors accuse the firm of promoting drugs (Duragesic and Nuncyta) that fueled overdose cases in the state. $572 Million Judgment Doesn't Phase Investors The ruling was […]
The post JNJ Stock Laughs Off $572 Million Opioid Fine With DJIA-Best Rally appeared first on CCN Markets
* First published on ccn.com
